Last Updated: July 10, 2026

AFEDITAB Drug Patent Profile

Name: AFEDITAB Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Afeditab, and what generic alternatives are available?

Afeditab is a drug marketed by Watson Labs and Watson Labs Teva and is included in two NDAs.

The generic ingredient in AFEDITAB is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Afeditab

A generic version of AFEDITAB was approved as nifedipine by ACTAVIS ELIZABETH on January 8^th, 1991.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for AFEDITAB?
What are the global sales for AFEDITAB?
What is Average Wholesale Price for AFEDITAB?

Summary for AFEDITAB

US Patents:	0
Applicants:	2
NDAs:	2
Drug Prices:	Drug price information for AFEDITAB
DailyMed Link:	AFEDITAB at DailyMed

Drug patent expirations by year for AFEDITAB

US Patents and Regulatory Information for AFEDITAB

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	AFEDITAB CR	nifedipine	TABLET, EXTENDED RELEASE;ORAL	075659-001	Oct 26, 2001		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs Teva	AFEDITAB CR	nifedipine	TABLET, EXTENDED RELEASE;ORAL	075128-001	Mar 10, 2000		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.